Scientists have just found a small molecule that can change how we lose weight

Scientists of the Salik Institute search for a new therapeutic strategy in micro proteins, a group of molecules across the body that play roles in both health and disease. In a new study, the researchers examined thousands of fat cell genes using the liberation of CRISPR genes to find dozens of genes that are likely to be a symbol of micro proteins – one of which – which regulates the proliferation of fat cells or fat accumulation.

The results published in The facts of the National Academy of Sciences On August 7, 2025, select the new micro proteins that can serve as drug targets for obesity and other metabolic disorders. The study also displays the value of CRISPR examination in the discovery of precise protein in the future.

“The CRISPR examination is very effective in finding important factors in obesity and metabolism that can become therapeutic goals,” said prominent author Alan Sagabayian, Professor and owner of Dr. Frederick Polsen in Salik. “The new examination techniques allow us to detect a fully new level of biological regulation that is driven by micro proteins. The more microbial proteins associated with diseases, and the potential goals we have to develop medicines in the future.”

Current obesity treatments and metabolic disorder

When our energy consumption exceeds our energy expenses, fat cells can grow in both size and number. O fat cells store the extra energy in the form of fatty molecules called fat. But although some excess storage can be controlled, many can cause fat deposits around the body-which leads to complete body inflammation and a functional disruption for organs.

Many factors organize this complex energy storage system. The problem is, how do we all find them, and how can we filter the factors that may make therapeutic candidates good?

This was a long question for Salik scientists. In fact, Professor Ronald Evans has been working for decades for decades. Evans is an expert in PPAR GAMMA, a major organizer for the development of fatty cells and a strong goal to treat diabetes. Several medications have been developed to target PPAR GAMMA to treat obesity, but have led to side effects such as weight gain and bone loss. It did not reach the ideal market that relies on PPAR GAMMA.

When PPAR GAMMA drugs fell, the GLP-1 drugs entered the scene. GLP-1 is a small peptide enough to be considered a small protein, and it is like a blood sugar regulator and an appetite regulator. However, like PPAR GAMMA, GLP-1 medications have their own shortcomings, such as muscle loss and nausea. However, the popularity of GLP-1 medications shows a promising future for precise protein medications in the therapeutic space of obesity.

The Saghatelian team is now looking for the following micro proteins with new genetic tools that bring precise proteins from “dark”. For many years, long periods of genome have been considered “undesirable” and thus left unexpected. However, modern technological developments allowed scientists to look at these dark sections and find a hidden world of micro proteins – in turn, expanding protein libraries by 10 to 30 percent.

In particular, the SALK team uses the innovative CRISPR inspection to perform “dark” for potential micro proteins. This approach enables the simultaneous detection of thousands of possible micro proteins involved in storing fats and fatty cell biology, which accelerates the search for the next PPAR GAMMA or GLP-1.

How to speed up the CRISPR examination to search for micro proteins

CRISPR screens work by canceling cells interest in cells and monitoring whether the cell flourishes or dies without them. Of these results, scientists can determine the importance and function of specific genes. In this case, the SALK team was interested in genes that might symbolize micro proteins involved in the distinction or multiplication of fat cells.

“We wanted to know if anything we had lost in all these years of research in the metabolism of the body,” says the first author Victor Bay, a post -PhD researcher at the Sagabayian Laboratory. “CRISPR allows us to choose interesting and functional genes that particularly affect the accumulation of fat and the development of fat cells.”

This last research is followed in a previous study of the Saghatelian Laboratory. The previous study identified thousands of potential micro proteins by analyzing RNA’s DNA thread coding precise protein derived from mouse fat tissue. These ripped DNA threads are lifted for exact protein to wait for an investigation of their functions.

The new study first expanded this group to include additional accurate proteins identified from the pre -fat cell model. It is worth noting that this new model picks up the differentiation process from the cell before fat to a fully mature sebaceous cell. After that, the researchers examined the cell model using CRISPR to determine the number of these possible micro proteins that participated in the differentiation or multiplication of fatty cells.

“We are not the first screen for micro proteins with Krisper, but we are the first to search for micro proteins participating in the reproduction of fat cells. This is a big step for metabolism and obesity research,” Bay added.

Micro -proteins of attention and the following steps

Using the mouse model and the CRISPR examination approach, the team select the micro proteins that may be involved in the biology of sebaceous cells. Then the assembly fed more with another experience to create a brief menu of 38 possible accurate proteins involved in the formation of a fat drop – indicating an increase in the storage of fat – during the distinction of fat cells.

At this stage, the micro proteins included in the brief list were still “potential” micro proteins. This is because the genetic examination finds the genes that may symbolize micro proteins, instead of finding the same micro proteins. Although this approach is a useful solution to find the micro -proteins that are very small, they mean capturing them, this also means that the exact proteins that are examined require more tests to confirm whether they are functional.

This is what Salik team did after that. They chose many brief proteins for the test and were able to check for one. PAI assumes this new precise protein, which is called SMORF-1183, affects the formation of a drop of fat in fat cells (also known as lipid cells).

Smorf-1183 lipid verification is an exciting step towards identifying more precision proteins involved in the accumulation of fat and regulating fat cells in obesity. It also checks that CRISPR is an effective tool for finding micro proteins involved in fatty cell biology, obesity and metabolism.

“This is the goal of research, right?” Sghaphelian says. “You continue. It is a continuous process of improvement as we create a better technique and a better function of work to enhance the discovery, and eventually the therapeutic results below the line.”

After that, the researchers will repeat the study with human fat cells. They also hope to inspire their other success to use CRISPR offers to continue to remove micro proteins from dark-such as SMORF-1183, which so far has been an unimportant part of “unimportant” DNA.

More verification of the health of cellular libraries or examining them will expand the list of potential drug candidates, which paves the way for new and improved obesity in the future.

Among the other authors, Hazel Chan, Sinatia Donaldson, Joan Fujan, Eduardo F. De Souza, Caroline O’Connor, and Michelle Liem from Salik; Antonio Pinto and Julien Deadich from the Scripps Research Institute.

This work was supported by the National Institutes of Health (F32 DK132927, RC2 DK129961, R01 dk106210, R01 GM102491, RF1 Ag086547, NCI CNCER Center P30 014195, S10-ded023689, Larry and Carol Greenfield Technology Fund.